RETROPHIN, INC. (NASDAQ:RTRX) Files An 8-K Results of Operations and Financial ConditionItem 2.02RESULTS OF OPERATIONS AND FINANCIAL CONDITION
On August 9, 2017, Retrophin, Inc. (the “Company”) issued a press release announcing, among other things, its financial results for the quarter ended June 30, 2017. A copy of the press release and accompanying information is attached as Exhibit 99.1 to this current report.
The information in this Item 2.02, and Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for the purposes of Section18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this Item 2.02, and Exhibit 99.1 attached hereto, shall not be incorporated by reference into any registration statement or other document filed with the Securities and Exchange Commission, whether filed before or after the date hereof regardless of any general incorporation language in any such filing, unless the registrant expressly sets forth in such filing that such information is to be considered “filed” or incorporated by reference therein.
Item 2.02FINANCIAL STATEMENTS AND EXHIBITS
|
99.1 |
Press release of Retrophin, Inc. dated August 9, 2017. |
Retrophin, Inc. ExhibitEX-99.1 2 earningsreleaseq22017.htm EXHIBIT 99.1 Exhibit Exhibit 99.1Contact:Chris Cline,…To view the full exhibit click here
About RETROPHIN, INC. (NASDAQ:RTRX)
Retrophin, Inc. is a biopharmaceutical company focused on the development, acquisition and commercialization of therapies for the treatment of serious, catastrophic or rare diseases. It sells three products, including Chenodal (chenodeoxycholic acid), Cholbam (cholic acid) and Thiola (tiopronin). Its Chenodal is approved in the United States for the treatment of patients suffering from gallstones in whom surgery poses an unacceptable health risk due to disease or advanced age. Chenodal has also been care for cerebrotendinous xanthomatosis (CTX) patients. Its Cholbam is approved in the United States for the treatment of bile acid synthesis disorders due to single enzyme defects and is further indicated for adjunctive treatment of patients with peroxisomal disorders. Its Thiola is approved in the United States for the prevention of cystine (kidney) stone formation in patients with severe homozygous cystinuria. Its product candidates include Sparsentan, RE-024, RE-034 and NGLY1.
